Prognostic indicators in node-negative early stage breast cancer

William W. Wong, Srinivasan Vijayakumar, Ralph R. Weichselbaum

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

With the increasing availability of screening mammography, more women are diagnosed as having breast cancers at an early, node-negative stage. The majority of these patients would be cured with total mastectomy or breast conservation treatment. However, about 30% of the patients would have recurrence of disease in distant sites. In recent randomized clinical trials, adjuvant systemic therapy has been shown to reduce the rate of recurrence in these patients. Proper selection of patients for adjuvant therapy is necessary to avoid exposing many patients with low risk of recurrence to treatments for whom the benefit is not justified by the toxicity and the cost. In this article, we review the clinical and pathologic prognostic factors in early stage, node-negative breast cancer patients, including tumor size, nuclear and histologic grades, estrogen and progesterone receptors, menopausal status, proliferative rate, HER2/neu oncogene amplification, and cathepsin D level. Favorable prognostic factors include tumor size less than or equal to 2 cm, low nuclear and histologic grades, low S-phase fraction, diploid state, low cathepsin-D level, and positive estrogen and progesterone receptor status. The value of HER-2/neu oncogene overexpression is controversial, and further studies are needed to define its role as a prognostic factor in patients with node-negative breast cancer. Based on these prognostic factors, it is possible to identify subsets of patients who have a low risk of recurrence and would not benefit significantly from adjuvant systemic therapy.

Original languageEnglish (US)
Pages (from-to)539-548
Number of pages10
JournalThe American journal of medicine
Volume92
Issue number5
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Breast Neoplasms
Recurrence
Cathepsin D
Progesterone Receptors
Oncogenes
Estrogen Receptors
Simple Mastectomy
Therapeutics
Mammography
Diploidy
S Phase
Patient Selection
Neoplasms
Breast
Randomized Controlled Trials
Costs and Cost Analysis

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Prognostic indicators in node-negative early stage breast cancer. / Wong, William W.; Vijayakumar, Srinivasan; Weichselbaum, Ralph R.

In: The American journal of medicine, Vol. 92, No. 5, 1992, p. 539-548.

Research output: Contribution to journalArticle

Wong, William W. ; Vijayakumar, Srinivasan ; Weichselbaum, Ralph R. / Prognostic indicators in node-negative early stage breast cancer. In: The American journal of medicine. 1992 ; Vol. 92, No. 5. pp. 539-548.
@article{1b678c4188f644db83ade2e9767ed903,
title = "Prognostic indicators in node-negative early stage breast cancer",
abstract = "With the increasing availability of screening mammography, more women are diagnosed as having breast cancers at an early, node-negative stage. The majority of these patients would be cured with total mastectomy or breast conservation treatment. However, about 30{\%} of the patients would have recurrence of disease in distant sites. In recent randomized clinical trials, adjuvant systemic therapy has been shown to reduce the rate of recurrence in these patients. Proper selection of patients for adjuvant therapy is necessary to avoid exposing many patients with low risk of recurrence to treatments for whom the benefit is not justified by the toxicity and the cost. In this article, we review the clinical and pathologic prognostic factors in early stage, node-negative breast cancer patients, including tumor size, nuclear and histologic grades, estrogen and progesterone receptors, menopausal status, proliferative rate, HER2/neu oncogene amplification, and cathepsin D level. Favorable prognostic factors include tumor size less than or equal to 2 cm, low nuclear and histologic grades, low S-phase fraction, diploid state, low cathepsin-D level, and positive estrogen and progesterone receptor status. The value of HER-2/neu oncogene overexpression is controversial, and further studies are needed to define its role as a prognostic factor in patients with node-negative breast cancer. Based on these prognostic factors, it is possible to identify subsets of patients who have a low risk of recurrence and would not benefit significantly from adjuvant systemic therapy.",
author = "Wong, {William W.} and Srinivasan Vijayakumar and Weichselbaum, {Ralph R.}",
year = "1992",
doi = "10.1016/0002-9343(92)90751-V",
language = "English (US)",
volume = "92",
pages = "539--548",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prognostic indicators in node-negative early stage breast cancer

AU - Wong, William W.

AU - Vijayakumar, Srinivasan

AU - Weichselbaum, Ralph R.

PY - 1992

Y1 - 1992

N2 - With the increasing availability of screening mammography, more women are diagnosed as having breast cancers at an early, node-negative stage. The majority of these patients would be cured with total mastectomy or breast conservation treatment. However, about 30% of the patients would have recurrence of disease in distant sites. In recent randomized clinical trials, adjuvant systemic therapy has been shown to reduce the rate of recurrence in these patients. Proper selection of patients for adjuvant therapy is necessary to avoid exposing many patients with low risk of recurrence to treatments for whom the benefit is not justified by the toxicity and the cost. In this article, we review the clinical and pathologic prognostic factors in early stage, node-negative breast cancer patients, including tumor size, nuclear and histologic grades, estrogen and progesterone receptors, menopausal status, proliferative rate, HER2/neu oncogene amplification, and cathepsin D level. Favorable prognostic factors include tumor size less than or equal to 2 cm, low nuclear and histologic grades, low S-phase fraction, diploid state, low cathepsin-D level, and positive estrogen and progesterone receptor status. The value of HER-2/neu oncogene overexpression is controversial, and further studies are needed to define its role as a prognostic factor in patients with node-negative breast cancer. Based on these prognostic factors, it is possible to identify subsets of patients who have a low risk of recurrence and would not benefit significantly from adjuvant systemic therapy.

AB - With the increasing availability of screening mammography, more women are diagnosed as having breast cancers at an early, node-negative stage. The majority of these patients would be cured with total mastectomy or breast conservation treatment. However, about 30% of the patients would have recurrence of disease in distant sites. In recent randomized clinical trials, adjuvant systemic therapy has been shown to reduce the rate of recurrence in these patients. Proper selection of patients for adjuvant therapy is necessary to avoid exposing many patients with low risk of recurrence to treatments for whom the benefit is not justified by the toxicity and the cost. In this article, we review the clinical and pathologic prognostic factors in early stage, node-negative breast cancer patients, including tumor size, nuclear and histologic grades, estrogen and progesterone receptors, menopausal status, proliferative rate, HER2/neu oncogene amplification, and cathepsin D level. Favorable prognostic factors include tumor size less than or equal to 2 cm, low nuclear and histologic grades, low S-phase fraction, diploid state, low cathepsin-D level, and positive estrogen and progesterone receptor status. The value of HER-2/neu oncogene overexpression is controversial, and further studies are needed to define its role as a prognostic factor in patients with node-negative breast cancer. Based on these prognostic factors, it is possible to identify subsets of patients who have a low risk of recurrence and would not benefit significantly from adjuvant systemic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0026603322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026603322&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(92)90751-V

DO - 10.1016/0002-9343(92)90751-V

M3 - Article

C2 - 1580300

AN - SCOPUS:0026603322

VL - 92

SP - 539

EP - 548

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5

ER -